Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, February 5, 2026 – Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the...
SAN DIEGO, January 26, 2026 – Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland...
– PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses – SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today...
— PRTX007 demonstrated a favorable safety profile for all analyzed cohorts with no serious adverse events (SAEs) observed — — Well-controlled activation of innate and adaptive immune response observed without increases in proinflammatory factors — — Data support...
SAN DIEGO, October 11, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small...
SAN DIEGO, May 8, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that...
